Baclofen to Reduce Alcohol Use in Veterans With HCV

Completed · Phase 4 · Has a placebo group

Conditions studied: Hepatitis C, Alcohol Use Disorders

In brief

Hepatitis C (HCV) is the most common blood born virus in the United States, affecting 1.8% of the general population and more than 5% of Veterans using VA facilities. As Veterans with HCV have high rates of co-morbid alcohol use disorders that accelerate greatly the liver damage caused by HCV, a safe and effective treatment for alcohol use disorders is needed. Baclofen is a novel treatment for alcohol use disorders that has minimal effect on the liver and may represent a safe and efficacious treatment option for Veterans with HCV and co-morbid alcohol use disorders.

Key facts

Study ID
NCT01008280
Run by
VA Office of Research and Development
People needed
180
Starts
2010-10-01
Expected to finish
2015-09-01
Last updated by the study team
2016-02-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.